Scottsdale, AZ – April 30, 2020 – Resonea, Inc., (“Resonea” or the “Company”) a technology company founded to create a new standard for understanding sleep and breathing and their long-term impact on health, wellness, performance, and quality of life, announced that they have been selected for membership in the Flinn Foundation Bioscience Entrepreneurship Program for 2020. The Phoenix-based Flinn Foundation operates a program that supports six early-stage companies per year with select services and $30,000 in funding through a non-profit partner as part of the Foundation’s strategic mission to build Arizona into a global leader for bioscience research and commercialization.
Recipients of this competitive program are selected based on their innovation in bioscience research and creation of technological solutions such as novel medical devices. In addition to receiving non-dilutive funding of $30,000, each company participates on the Bioscience Roadmap Steering Committee and receives specialized support from a commercialization expert.
Resonea has developed the DROWZLE Sleep Health Program (DSHP) to provide education, screening, condition management, and follow-up for sleep health and sleep disorders such as obstructive sleep apnea (OSA). DSHP includes DROWZLE® PRO, an FDA-cleared proprietary software and analytical algorithm for detection and monitoring of OSA. This system is deployed on consumer smartphones and is the first digital home sleep test.
“We are thrilled to have the opportunity to participate in the Flinn Foundation Biopreneur program,” said Karen Underwood, MD, Chief Medical Officer and co-founder of Resonea. “Sleep breathing disorders are common, costly, dangerous and often worsen other chronic health conditions. There is a massive need for more innovative detection methods. The funding will help us to demonstrate the value of DROWZLE PRO for in-home screening of adults with suspected sleep breathing disorders, through our Early Experience Reference Sites.”